MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...
Applications for the 2025/2026 academic year are no longer being accepted. Successful candidates will be contacted by NorQuest College. The next intake period will begin in the summer of 2026. The ...
Program applications are currently closed. Check back for the 2026-27 program intake, opening in spring 2026. sustain healthy fish and wildlife populations conserve ecological services that benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback